睿知中国医院研究地图
候选清单

即将招募胃癌I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

SND002 Cell Injection in Participants With Advanced Malignant Solid Tumors

ClinicalTrials.gov 上登记的一项胃癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心浙江大学医学院附属第一医院First Affiliated Hospital, Zhejiang University杭州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07903857,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 80 岁;性别:不限

    登记记录的入选字段

  2. Negative serum pregnancy test within 7 days before enrollment for women of childbearing potential. All participants of childbearing potential must agree to use effective contraception from enrollment until at least 6 months after SND002 Cell Injection infusion. A woman is considered not of childbearing potential if she meets at least one of the following: prior hysterectomy or bilateral oophorectomy; medically confirmed ovarian failure; medically confirmed physiological amenorrhea for at least 12 consecutive months, excluding chemotherapy, radiotherapy, or sex hormone therapy and other pathological causes.

    入选标准第 20 条

  3. Part B (expansion), cohort 1 (colorectal cancer): at least two lines of prior systemic standard therapy, including a fluoropyrimidine plus oxaliplatin and/or irinotecan, with or without targeted therapy (bevacizumab or cetuximab) and with or without immunotherapy (programmed cell death protein 1 or programmed death-ligand 1 inhibitors; microsatellite instability-high or mismatch repair-deficient tumors must have received this therapy), with disease progression or intolerance during or after the last dose.

    入选标准第 5 条

    Part B, cohort 2 (gastric cancer): at least two lines of prior systemic standard therapy, including a platinum agent and/or a fluoropyrimidine, with or without immunotherapy (programmed cell death protein 1 or programmed death-ligand 1 inhibitors) and with or without a taxane; human epidermal growth factor receptor 2-positive tumors must have received anti-human epidermal growth factor receptor 2 therapy, with disease progression or intolerance during or after the last dose.

    入选标准第 6 条

    Part B, cohort 3 (other solid tumors): tumors anticipated to respond based on dose-escalation data, potentially including malignant melanoma, pancreatic cancer, hepatic cancer, biliary tract cancer, cervical cancer, ovarian cancer, endometrial cancer, breast cancer, and lung cancer; at least one line of prior standard therapy according to the relevant guideline, with disease progression or intolerance during or after the last dose.

    入选标准第 7 条

    Toxicities from prior therapy resolved to Grade 1 or lower before enrollment, except alopecia and Grade 2 or lower neuropathy caused by chemotherapy.

    入选标准第 19 条

    Systemic antitumor therapy within 4 weeks before preconditioning, except bridging therapy. For prior nitrosourea or mitomycin chemotherapy, the interval to preconditioning must be at least 6 weeks. For prior small-molecule targeted therapy, the interval must be at least 5 half-lives.

    排除标准第 3 条

  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

    入选标准第 3 条

  5. Absolute neutrophil count at least 1.0x10\^9/L.

    入选标准第 12 条

    Platelet count at least 80x10\^9/L.

    入选标准第 13 条

    Hemoglobin at least 80 g/L.

    入选标准第 14 条

    Serum total bilirubin no more than 1.5 times the upper limit of normal (ULN); no more than 3 times ULN in participants with Gilbert syndrome or hepatic metastasis.

    入选标准第 15 条

    Alanine aminotransferase and aspartate aminotransferase no more than 2.5 times ULN; no more than 5 times ULN in participants with hepatic metastasis.

    入选标准第 16 条

    International normalized ratio no more than 1.5 times ULN and activated partial thromboplastin time no more than 1.5 times ULN, except in participants receiving anticoagulation.

    入选标准第 17 条

    Creatinine clearance at least 60 mL/min calculated by the Cockcroft-Gault formula.

    入选标准第 18 条

  6. Other malignancy within 5 years before screening or concurrently, except malignancy treated locally and cured with no antitumor therapy required for at least 1 year, such as non-melanoma skin cancer or cervical carcinoma in situ.

    排除标准第 6 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07903857,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Provision of written informed consent before any study-specific procedure, and ability to complete the study procedures and follow-up assessments.
  2. Age 18 to 80 years inclusive at the time of informed consent. Participants older than 80 years may be enrolled at the joint discretion of the investigator and the sponsor.
  3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  4. Part A (dose escalation): cytologically or histologically confirmed advanced malignant solid tumor, including but not limited to gastrointestinal tumors (colorectal, gastric, pancreatic, hepatic, and biliary tract), gynecologic tumors (cervical, ovarian, and endometrial), breast cancer, malignant melanoma, and lung cancer. Prior therapy must meet at least one of the following: (a) at least one line of systemic standard therapy for advanced or metastatic disease, with disease progression during or after the last dose, or intolerance (Grade 3 or higher irreversible toxicity); (b) no recognized standard treatment available as judged by the investigator; (c) inability to receive current standard treatment for specific reasons.
  5. Part B (expansion), cohort 1 (colorectal cancer): at least two lines of prior systemic standard therapy, including a fluoropyrimidine plus oxaliplatin and/or irinotecan, with or without targeted therapy (bevacizumab or cetuximab) and with or without immunotherapy (programmed cell death protein 1 or programmed death-ligand 1 inhibitors; microsatellite instability-high or mismatch repair-deficient tumors must have received this therapy), with disease progression or intolerance during or after the last dose.
  6. Part B, cohort 2 (gastric cancer): at least two lines of prior systemic standard therapy, including a platinum agent and/or a fluoropyrimidine, with or without immunotherapy (programmed cell death protein 1 or programmed death-ligand 1 inhibitors) and with or without a taxane; human epidermal growth factor receptor 2-positive tumors must have received anti-human epidermal growth factor receptor 2 therapy, with disease progression or intolerance during or after the last dose.
  7. Part B, cohort 3 (other solid tumors): tumors anticipated to respond based on dose-escalation data, potentially including malignant melanoma, pancreatic cancer, hepatic cancer, biliary tract cancer, cervical cancer, ovarian cancer, endometrial cancer, breast cancer, and lung cancer; at least one line of prior standard therapy according to the relevant guideline, with disease progression or intolerance during or after the last dose.
  8. Availability of at least one draining lymph node suitable for product manufacture, obtainable by conventional surgery or interventional procedure, or use of stored draining lymph node cells. Sentinel lymph node tissue is preferred when obtainable. The interval from prior radiotherapy or radiofrequency ablation to collection should preferably exceed 3 months.
  9. At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), excluding the lesion used for lymph node collection, which may serve only as a non-target lesion even if measurable.
  10. Life expectancy of at least 3 months.
  11. Adequate organ function, with laboratory results meeting all of the following within 14 days before enrollment and without platelet transfusion or colony-stimulating factor administration during that period:
  12. Absolute neutrophil count at least 1.0x10\^9/L.
  13. Platelet count at least 80x10\^9/L.
  14. Hemoglobin at least 80 g/L.
  15. Serum total bilirubin no more than 1.5 times the upper limit of normal (ULN); no more than 3 times ULN in participants with Gilbert syndrome or hepatic metastasis.
  16. Alanine aminotransferase and aspartate aminotransferase no more than 2.5 times ULN; no more than 5 times ULN in participants with hepatic metastasis.
  17. International normalized ratio no more than 1.5 times ULN and activated partial thromboplastin time no more than 1.5 times ULN, except in participants receiving anticoagulation.
  18. Creatinine clearance at least 60 mL/min calculated by the Cockcroft-Gault formula.
  19. Toxicities from prior therapy resolved to Grade 1 or lower before enrollment, except alopecia and Grade 2 or lower neuropathy caused by chemotherapy.
  20. Negative serum pregnancy test within 7 days before enrollment for women of childbearing potential. All participants of childbearing potential must agree to use effective contraception from enrollment until at least 6 months after SND002 Cell Injection infusion. A woman is considered not of childbearing potential if she meets at least one of the following: prior hysterectomy or bilateral oophorectomy; medically confirmed ovarian failure; medically confirmed physiological amenorrhea for at least 12 consecutive months, excluding chemotherapy, radiotherapy, or sex hormone therapy and other pathological causes.
  21. Ability to recognize and comply with the protocol as judged by the investigator.

排除标准:Exclusion Criteria:

  1. More than 3 untreated central nervous system metastases at screening. Participants with 3 or fewer central nervous system metastases may be enrolled if the largest diameter is less than 1 cm, there is no peritumoral edema on brain imaging, and there is no evidence of progressive central nervous system disease on brain imaging at least 3 months after treatment.
  2. Prior adoptive cell therapy, including dendritic cells, cytokine-induced killer cells, T cells, natural killer cells, or chimeric antigen receptor T cells.
  3. Systemic antitumor therapy within 4 weeks before preconditioning, except bridging therapy. For prior nitrosourea or mitomycin chemotherapy, the interval to preconditioning must be at least 6 weeks. For prior small-molecule targeted therapy, the interval must be at least 5 half-lives.
  4. Systemic corticosteroids at a dose of 10 mg/day or more of prednisone or equivalent, or other immunosuppressive therapy, within 2 weeks before preconditioning, except inhaled, topical, or physiological replacement therapy.
  5. Major surgery within 4 weeks before screening, or planned major surgery during the study other than the protocol-specified procedure for lymph node collection.
  6. Other malignancy within 5 years before screening or concurrently, except malignancy treated locally and cured with no antitumor therapy required for at least 1 year, such as non-melanoma skin cancer or cervical carcinoma in situ.
  7. Active autoimmune disease, a history of autoimmune disease, or a condition requiring systemic corticosteroids or immunosuppressive therapy at more than 10 mg/day of prednisone or equivalent.
  8. History of organ transplantation or hematopoietic stem cell transplantation.
  9. Infectious disease within 1 year before screening, including positive human immunodeficiency virus, syphilis, or cytomegalovirus DNA; active pulmonary tuberculosis, or a history of active pulmonary tuberculosis for more than 1 year without adequate treatment; positive hepatitis B surface antigen, or positive hepatitis B core antibody with hepatitis B virus DNA above the lower limit of normal at the study site; positive hepatitis C virus antibody with hepatitis C virus RNA above the lower limit of normal. Inactive carriers may participate if antiviral therapy is arranged as appropriate and nucleic acid levels are monitored periodically during the study.
  10. Live or attenuated vaccine within 4 weeks before preconditioning.
  11. Clinically significant cardiovascular disease, including but not limited to:
  12. Congestive heart failure classified as New York Heart Association class higher than 2.
  13. Unstable angina.
  14. Myocardial infarction within the past 3 months.
  15. Any supraventricular or ventricular arrhythmia requiring treatment or intervention.
  16. Interstitial pneumonia, clinically significant active pneumonia at screening, or other respiratory disease that significantly affects lung function.
  17. Refractory or intractable epilepsy, pleural effusion, ascites, or pericardial effusion not controlled by medication, active gastrointestinal bleeding, or any contraindication to interleukin-2.
  18. History of hypersensitivity to any component of the study drugs, including but not limited to SND002 Cell Injection, cyclophosphamide, fludarabine, interleukin-2, dimethyl sulfoxide (DMSO), human serum albumin, or gentamicin.
  19. Treatment with another investigational product within 4 weeks before screening, or planned participation in another investigational product study during the study.
  20. Any other condition the investigator considers unsuitable for participation, for example Grade 3 or higher adverse reactions with prior immunotherapy.

引自 ClinicalTrials.gov, NCT07903857, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07903857,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07903857